“PIK”选择合适的患者进行结肠直肠癌的阿司匹林辅助治疗。

IF 10.2 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-08-01 DOI:10.1158/1078-0432.CCR-25-0953

David A Drew, Jonathan M Downie, Andrew T Chan

{"title":"“PIK”选择合适的患者进行结肠直肠癌的阿司匹林辅助治疗。","authors":"David A Drew, Jonathan M Downie, Andrew T Chan","doi":"10.1158/1078-0432.CCR-25-0953","DOIUrl":null,"url":null,"abstract":"Observational studies demonstrate that aspirin use after diagnosis of colorectal cancer, particularly tumors with mutated PIK3CA, improves outcomes. However, randomized controlled trial data are lacking. In this issue, we discuss the SAKK 41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action. See related article by Güller et al., p. 3142.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"3107-3109"},"PeriodicalIF":10.2000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"\\\"PIK\\\"ing the Right Patients for Adjuvant Aspirin Therapy for Colorectal Cancer.\",\"authors\":\"David A Drew, Jonathan M Downie, Andrew T Chan\",\"doi\":\"10.1158/1078-0432.CCR-25-0953\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Observational studies demonstrate that aspirin use after diagnosis of colorectal cancer, particularly tumors with mutated PIK3CA, improves outcomes. However, randomized controlled trial data are lacking. In this issue, we discuss the SAKK 41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action. See related article by Güller et al., p. 3142.\",\"PeriodicalId\":10279,\"journal\":{\"name\":\"Clinical Cancer Research\",\"volume\":\" \",\"pages\":\"3107-3109\"},\"PeriodicalIF\":10.2000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1078-0432.CCR-25-0953\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.CCR-25-0953","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

观察性研究表明，在结直肠癌诊断后使用阿司匹林，特别是PIK3CA突变的肿瘤，可改善预后。然而，缺乏随机对照试验数据。在这里，我们讨论SAKK41/13辅助阿司匹林随机对照试验结果，以及其他辅助阿司匹林试验和潜在作用机制的新数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

"PIK"ing the Right Patients for Adjuvant Aspirin Therapy for Colorectal Cancer.

Observational studies demonstrate that aspirin use after diagnosis of colorectal cancer, particularly tumors with mutated PIK3CA, improves outcomes. However, randomized controlled trial data are lacking. In this issue, we discuss the SAKK 41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action. See related article by Güller et al., p. 3142.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.